<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65283">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01692938</url>
  </required_header>
  <id_info>
    <org_study_id>OPT1001</org_study_id>
    <nct_id>NCT01692938</nct_id>
  </id_info>
  <brief_title>Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO</brief_title>
  <official_title>Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optos, PLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Optos, PLC.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To conduct a precision study to assess the microperimetry function of the Spectral OCT/SLO.
      The study will assess variability across measurements taken by three different
      operator-device configuration across clinical sites, variability between subjects within a
      given operator-device configuration, and variability within a subject for a single
      operator-device configuration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Age-Related Macular Degeneration,</condition>
  <condition>Geographic Atrophy,</condition>
  <condition>Diabetic Retinopathy,</condition>
  <condition>Macular Edema,</condition>
  <condition>Retinal Vein Occlusion,</condition>
  <condition>Central Serous Retinopathy,</condition>
  <condition>Pattern Dystrophy of Macula</condition>
  <condition>Epiretinal Membrane,</condition>
  <condition>Macular Hole.</condition>
  <arm_group>
    <arm_group_label>No Retinal Disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinal Disease</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Twenty-four subjects, 12 without retinal disease (Cohort 1) and 12 with retinal disease
        (Cohort 2) will be recruited. Any subjects that do not comply with or complete the study
        protocol will be replaced to ensure that a total of 24 subjects complete the protocol.
        Subjects will be screened and recruited based on the Inclusion/Exclusion criteria outlined
        within this protocol.  Subjects fulfilling the stated criteria and who are willing to
        comply must sign an informed consent prior form to study participation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be 21 years of age or older.

          -  Subjects recruited to Cohort 1 will have no known retinal disease except for
             refractive errors (-7.5 D to +7.5 diopters).Subjects who are recruited to Cohort 2
             will have one or more of the following retinal pathologies: early and intermediate
             Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy (mild,
             moderate, severe), Macular Edema secondary to Diabetes, Retinal Vein Occlusion,
             Central Serous Retinopathy, Pattern Dystrophy, Epiretinal Membrane or Macular Hole.

          -  Subjects who have signed an informed consent form.

          -  Subjects who can comply with the protocol.

        Exclusion Criteria:

          -  Subjects younger than 21 years of age.

          -  Subjects who cannot comply with the protocol.

          -  Subjects who cannot complete the Simple Test procedures

          -  Subjects who are not available to be testing 3 times during the day (Morning, Mid -
             Day, and Afternoon).

          -  Subjects with visual acuity worse than 20/100 (Best Corrected).

          -  Subjects with dense media opacities.

          -  Ocular surgery anticipated on the day of the study visit.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quan Nguyen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC, Doheny Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Srinivas Sadda, MD</last_name>
    </contact>
    <investigator>
      <last_name>Srinivas Sadda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Group of Florida</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence S Halperin, MD</last_name>
      <phone>954-776-6880</phone>
    </contact>
    <investigator>
      <last_name>Lawrence S Halperin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Unversity</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quan Nguyen, MD</last_name>
      <phone>410-502-9821</phone>
    </contact>
    <contact_backup>
      <last_name>Hongting Liu</last_name>
    </contact_backup>
    <investigator>
      <last_name>Quan Nguyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Gonzalez, MD</last_name>
      <phone>956-631-8875</phone>
    </contact>
    <investigator>
      <last_name>Victor Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>October 28, 2012</lastchanged_date>
  <firstreceived_date>September 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Perforations</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Epiretinal Membrane</mesh_term>
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
